MedPath

CAR T-cell Therapy Shows Promise in Treating B-cell Lymphoma

Recent studies highlight the effectiveness of CAR T-cell therapy in treating aggressive B-cell lymphoma, with significant response rates and manageable adverse events. Real-world data and long-term follow-ups support its use, despite challenges like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Aggressive B-cell Lymphoma

CAR T-cell therapy, specifically axicabtagene ciloleucel (axi-cel), has shown remarkable efficacy in treating aggressive B-cell lymphoma. The ZUMA-1 study, a phase 2 trial, demonstrated an overall response rate (ORR) of 82% and a complete response (CR) rate of 54% in patients with refractory or relapsed (R/R) disease. With a median follow-up of 15 months, 42% of patients maintained an objective response, and the overall survival (OS) at 18 months was 52%. Adverse events included neutropenia, anemia, and thrombocytopenia, with grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) occurring in 13% and 28% of patients, respectively.
Real-world studies have corroborated these findings, showing similar efficacy and safety profiles. For instance, a study led by Jacobson observed a best ORR of 70% and a CR rate of 50% among 122 patients treated with axi-cel. Another study by Nastoupil reported an ORR of 82% and a CR rate of 64% in 275 patients, with grade ≥ 3 CRS and ICANS occurring in 7% and 31% of patients, respectively.
Long-term follow-up studies have also shed light on the durability of responses and the importance of prophylactic anti-microbials and long-term immune surveillance post-therapy.

Tisagenlecleucel and Lisocabtagene Maraleucel

Tisagenlecleucel (tisa-cel) has been evaluated in the JULIET study, showing an ORR of 52% and a CR rate of 40% in adults with R/R diffuse large B-cell lymphoma (DLBCL). The TRANSCEND-NHL 001 study assessed lisocabtagene maraleucel (liso-cel) across various B-cell lymphomas, reporting an ORR of 73% and a CR rate of 53%. Both therapies have demonstrated manageable safety profiles, with improvements in health-related quality of life (HRQoL) observed in responders.

Special Considerations and Future Directions

Pretreatment comorbidities and bridging therapy have been identified as factors influencing outcomes. The impact of bridging therapy on progression-free survival (PFS) and OS remains under investigation, with prospective studies needed to define optimal strategies.
Despite the exclusion of patients with central nervous system (CNS) involvement in pivotal trials, anecdotal reports suggest potential benefits of CAR T-cell therapy in this population, warranting further study.
Overall, CAR T-cell therapy represents a significant advancement in the treatment of R/R aggressive B-cell lymphoma, with ongoing research aimed at optimizing its use and exploring its application in other B-cell lymphoma subtypes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Off-the-Shelf CAR-NK Cell Therapy Shows Promise in B-Cell Lymphomas

A Phase 1 clinical trial of FT596, an off-the-shelf CAR-NK cell therapy, demonstrates its safety in patients with various types of B-cell lymphoma.
The study indicates that FT596 could be a less toxic alternative to CAR-T cell therapies, with potential for broader accessibility and reduced manufacturing costs.

CAR T-Cell Therapies Show Sustained Efficacy in Real-World Settings Post-FDA Approval

CAR T-cell therapies, since 2017, have consistently demonstrated effectiveness and safety in treating specific blood cancers, as shown in clinical trials.
Real-world data mirrors clinical trial outcomes, indicating that CAR T-cell therapy maintains its efficacy and safety profiles post-FDA approval.

Novel Therapies Show Promise in Relapsed/Refractory CLL After BTK Inhibitor and Venetoclax Failure

Emerging data highlight the increasing need for effective treatments for chronic lymphocytic leukemia (CLL) patients who progress after covalent BTK inhibitors and venetoclax.
Lisocabtagene ciloleucel (liso-cel; Breyanzi) has received FDA approval for CLL patients with 2 or more prior lines of therapy, demonstrating a complete response rate in a subset of patients.

CAR T-Cell Therapy Demonstrates Efficacy and Manageable Safety in Relapsed/Refractory Mantle Cell Lymphoma

A meta-analysis of 16 studies shows CAR T-cell therapy yields an 89% overall response rate and a 74% complete remission rate in relapsed/refractory MCL patients.
The analysis indicates 6- and 12-month progression-free survival rates of 68% and 51%, respectively, and overall survival rates of 80% and 69%.

Novel CAR T-cell Therapy AT101 Shows 100% Complete Response in Early Phase I Trial for NHL

AT101, a novel CAR T-cell therapy targeting a distinct CD19 epitope, demonstrates a 100% complete response rate at higher doses in a Phase I trial.
The first-in-human trial involved 12 patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) in South Korea.

NXC-201 CAR T-Cell Therapy Shows Promise in Relapsed/Refractory AL Amyloidosis

NXC-201, a BCMA-directed CAR T-cell therapy, demonstrated a 100% hematologic overall response rate in relapsed/refractory AL amyloidosis patients.
Organ responses were observed in 5 of 9 evaluable patients, indicating potential clinical benefit beyond hematologic improvement.

Axicabtagene Ciloleucel Shows Promise as Second-Line Therapy for Aggressive B-Cell Lymphoma

Axicabtagene ciloleucel (axi-cel) demonstrated a 71% complete metabolic response rate at 3 months in patients with relapsed or refractory aggressive B-cell lymphoma ineligible for stem cell transplant.
The study reported a manageable safety profile, with cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome being the most common adverse events.

Real-World Study Affirms Axicabtagene Ciloleucel's Efficacy in LBCL, Expanding Patient Eligibility

A real-world study of 1297 patients confirms the efficacy of axicabtagene ciloleucel (axi-cel) in relapsed/refractory large B-cell lymphoma (LBCL).
Patients ineligible for the ZUMA-1 trial, often due to comorbidities, still experienced durable responses with axi-cel treatment.

Innovative CAR T-cell and Oncolytic Virus Therapies Show Promise in Treating Aggressive Cancers

Elicera Therapeutics AB is advancing novel treatments for aggressive cancers, including a CAR T-cell therapy targeting CD20 for relapsed Non-Hodgkin's B-cell lymphoma and a new CAR T-cell therapy for glioblastoma. Additionally, their oncolytic virus, AdVince, is in clinical trials for neuroendocrine tumors, showcasing potential for both local tumor destruction and systemic immune response.

Advancements in CAR-Modified T Cells for Leukemia Treatment

Recent developments in cellular immunotherapy have introduced CAR-modified T cells targeting the CD19 antigen as a promising strategy for treating B-cell cancers. Despite challenges in clinical trial design and CAR structure, early trials show potential for significant impact on disease progression.

Reference News

[1]
CAR T-cell therapy for B-cell lymphoma - PMC
pmc.ncbi.nlm.nih.gov · Dec 25, 2021

Studies on axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for aggressive B-cell lymphoma showed high ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy